TM ‐233, a novel analog of 1′‐acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK / STAT and proteasome activities-Reference-Cited by-同舟云学术

TM ‐233, a novel analog of 1′‐acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK / STAT and proteasome activities

Published:2015-03-10 Issue:4 Volume:106 Page:438-446
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Sagawa Morihiko¹,Tabayashi Takayuki¹,Kimura Yuta¹,Tomikawa Tatsuki¹,Nemoto‐Anan Tomoe¹,Watanabe Reiko¹,Tokuhira Michihide¹,Ri Masaki²,Hashimoto Yuichi³,Iida Shinsuke²,Kizaki Masahiro¹

Affiliation:

1. Department of Hematology Saitama Medical Center Saitama Medical University Kawagoe Japan

2. Department of Medical Oncology and Immunology Nagoya City University Nagoya Japan

3. Institute of Molecular and Cellular Biosciences Tokyo University Tokyo Japan

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.12616

Reference37 articles.

1. Multiple myeloma

2. Multiple Myeloma

3. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

4. An overview of the progress in the treatment of multiple myeloma

5. Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers;Cancers;2021-10-14

2. Multiple Myeloma Inhibitory Activity of Plant Natural Products;Cancers;2021-05-29

3. 1′-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells;Planta Medica;2021-01-14

4. Targeting MCL-1 in hematologic malignancies: Rationale and progress;Blood Reviews;2020-11

5. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors;Cancer Medicine;2020-07-06